Home / Research / Taku Kikuchi TK Researcher profile · from public sources
Taku Kikuchi Targets Filled chips are declared by the researcher; the others come from publications (number of works).
Now Trials, publications and grants since Nov 2024.
Publication
Pre-CAR-HEMATOTOX at Leukapheresis Predicts Delayed Platelet Recovery After Idecabtagene Vicleucel in Multiple Myeloma.
Clinical lymphoma, myeloma & leukemia, Jul 2026
Publication
Publisher Correction: Smoldering multiple myeloma: advances in diagnosis and risk stratification, and evolving therapeutic strategies.
International journal of hematology, Jul 2026
Publication
Real-world outcomes of idecabtagene vicleucel in relapsed/refractory multiple myeloma: A single-centre experience.
British journal of haematology, Jun 2026
Publication
Impact of Intensive Cyclophosphamide-Containing Multi-Agent Bridging Therapy on Outcomes after Idecabtagene Vicleucel in Multiple Myeloma.
Transplantation and cellular therapy, Mar 2026
Publication
Prognostic significance of cardiac biomarkers in patients with AL amyloidosis treated with a daratumumab-based regimen.
Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis, Jan 2026
Publication
Outcomes of elranatamab in relapsed/refractory multiple myeloma: prognostic impact of monocyte count, MyCARe, and R2-ISS.
International journal of hematology, Dec 2025
Publication
Baseline Cytomegalovirus Immunoglobulin G Levels Predict Reactivation in Patients With Multiple Myeloma Receiving Elranatamab.
EJHaem, Nov 2025
Publication
Cytomegalovirus Retinitis During Idecabtagene Vicleucel Therapy in Patients With Relapsed/Refractory Multiple Myeloma.
Transplant infectious disease : an official journal of the Transplantation Society, Apr 2025
Co-authors Who links you Enter another researcher's profile link or ID to see who has published with both of you.
Is this you? Request a correction or removal: support@frontlightresearch.com
Report an error